465 related articles for article (PubMed ID: 15136788)
1. Inflammatory resolution: new opportunities for drug discovery.
Gilroy DW; Lawrence T; Perretti M; Rossi AG
Nat Rev Drug Discov; 2004 May; 3(5):401-16. PubMed ID: 15136788
[No Abstract] [Full Text] [Related]
2. From willow bark to peptides: the ever widening spectrum of NF-kappaB inhibitors.
D'Acquisto F; Ianaro A
Curr Opin Pharmacol; 2006 Aug; 6(4):387-92. PubMed ID: 16781194
[TBL] [Abstract][Full Text] [Related]
3. Lipoxins and new lipid mediators in the resolution of inflammation.
Schwab JM; Serhan CN
Curr Opin Pharmacol; 2006 Aug; 6(4):414-20. PubMed ID: 16750421
[TBL] [Abstract][Full Text] [Related]
4. Advances in anti-inflammatory therapy.
Cunningham FM; Lees P
Br Vet J; 1994; 150(2):115-34. PubMed ID: 7912989
[TBL] [Abstract][Full Text] [Related]
5. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution.
Serhan CN
Prostaglandins Leukot Essent Fatty Acids; 2005; 73(3-4):141-62. PubMed ID: 16005201
[TBL] [Abstract][Full Text] [Related]
6. [Basis and norms of utilization of anti-inflammatory drugs in dental surgery--2d part].
Gregori C
Ars Curandi Odontol; 1974; 1(4):43, 46-7, 49-51. PubMed ID: 4157218
[No Abstract] [Full Text] [Related]
7. Will non-steroid approaches to the treatment of inflammation replace our need for glucocorticoids?
Whelan CJ
Curr Opin Investig Drugs; 2003 May; 4(5):536-43. PubMed ID: 12833646
[TBL] [Abstract][Full Text] [Related]
8. Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX.
Chiang N; Arita M; Serhan CN
Prostaglandins Leukot Essent Fatty Acids; 2005; 73(3-4):163-77. PubMed ID: 16125378
[TBL] [Abstract][Full Text] [Related]
9. Nuclear factor (NF)-kappaB proteins: therapeutic targets.
Verma IM
Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii57-ii61. PubMed ID: 15479873
[No Abstract] [Full Text] [Related]
10. Cyclopentenone prostaglandins-new allies in the war on inflammation.
Willoughby DA; Moore AR; Colville-Nash PR
Nat Med; 2000 Feb; 6(2):137-8. PubMed ID: 10655096
[No Abstract] [Full Text] [Related]
11. Can NF-kappaB be a target for novel and efficient anti-cancer agents?
Olivier S; Robe P; Bours V
Biochem Pharmacol; 2006 Oct; 72(9):1054-68. PubMed ID: 16973133
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of glucocorticoid receptor signaling during inflammation.
Smoak KA; Cidlowski JA
Mech Ageing Dev; 2004; 125(10-11):697-706. PubMed ID: 15541765
[TBL] [Abstract][Full Text] [Related]
13. [The pharmacological regulation of inflammation: the current problems and developmental outlook].
Klebanov BM
Eksp Klin Farmakol; 1992; 55(4):4-8. PubMed ID: 1458187
[TBL] [Abstract][Full Text] [Related]
14. [Pathogenesis and treatment of nonallergic drug-hypersesitivity (focus on ace inhibitor and NSAIDs)].
Taniguchi M
Arerugi; 2007 Dec; 56(12):1475-84. PubMed ID: 18195550
[No Abstract] [Full Text] [Related]
15. Roles of NF-kappaB in health and disease: mechanisms and therapeutic potential.
Wong ET; Tergaonkar V
Clin Sci (Lond); 2009 Mar; 116(6):451-65. PubMed ID: 19200055
[TBL] [Abstract][Full Text] [Related]
16. Lipoxins and aspirin-triggered lipoxins in neutrophil adhesion and signal transduction.
Filep JG; Khreiss T; József L
Prostaglandins Leukot Essent Fatty Acids; 2005; 73(3-4):257-62. PubMed ID: 15979865
[TBL] [Abstract][Full Text] [Related]
17. The role of aspirin-triggered lipoxins in the mechanism of action of aspirin.
Gilroy DW
Prostaglandins Leukot Essent Fatty Acids; 2005; 73(3-4):203-10. PubMed ID: 15978791
[TBL] [Abstract][Full Text] [Related]
18. [Nuclear factor kappa B in the treatment of inflammatory and tumor diseases].
Lenícek M; Muchová L; Vítek L
Cas Lek Cesk; 2004; 143(10):680-4. PubMed ID: 15584618
[TBL] [Abstract][Full Text] [Related]
19. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines.
Thurmond RL; Gelfand EW; Dunford PJ
Nat Rev Drug Discov; 2008 Jan; 7(1):41-53. PubMed ID: 18172439
[TBL] [Abstract][Full Text] [Related]
20. New endogenous anti-inflammatory and proresolving lipid mediators: implications for rheumatic diseases.
Yacoubian S; Serhan CN
Nat Clin Pract Rheumatol; 2007 Oct; 3(10):570-9; quiz 1 p following 589. PubMed ID: 17906612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
